Vikram Sinha
Senior Vice President, Translational and Quantitative Medicine, Pioneering Medicines
Vikram Sinha joined Flagship Pioneering in 2026 and serves as Senior Vice President, Translational and Quantitative Medicine. In this role, he is responsible for translational medicine, clinical pharmacology and application of predictive models for clinical development at Pioneering Medicines and provides strategic oversight across a diverse portfolio of therapeutics, guiding decisions from target validation and candidate selection through proof-of-concept and regulatory submissions.
Vikram is a biopharmaceutical research and development executive-scientist with more than 25 years of experience leading translational medicine, clinical pharmacology, pharmacometrics, and quantitative sciences across the drug development continuum. He has held scientific and executive leadership roles in both large pharmaceutical companies, including Novartis, Merck, and Lilly, and as a Division Director at CDER/USFDA where he established and scaled capabilities in clinical pharmacology, translational science, and quantitative drug development. He has led global teams supporting numerous development programs across immunology, inflammation, nephrology, metabolic disorders, rare diseases, oncology, and specialty medicines. His work has contributed to multiple regulatory submissions and approvals worldwide.
Vikram is widely recognized as a thought leader in model-informed drug development and quantitative systems pharmacology. He has advanced innovative translational approaches to deepen understanding of disease biology, optimize dose selection, predict clinical outcomes, and strengthen portfolio decisions. His leadership has helped organizations improve development efficiency, reduce risk, and increase the probability of technical and regulatory success.
He holds a Ph.D. in Pharmaceutical Sciences from the University of Arizona and has authored numerous scientific publications, research patents, presentations, advisory panels, and contributions in the fields including regulatory guidance and academic consortia.